89. リンパ脈管筋腫症 Disease details / Clinical trials / Drug dev / DR info

68GA-NEB
   Peking Union Medical College Hospital
      2019   Phase 1   NCT04273334   China
Acetate
   Brigham and Women's Hospital
      2021   Phase 1/Phase 2   NCT05467397   United States
Afinitor
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
Afinitor 5MG tablets
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
Albuterol inhaler
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States
Albuterol nebulizer
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States
Assessment OF arterial stiffness using THE vasera VS-1500N
   I.M. Sechenov First Moscow State Medical University
      2023   -   NCT05727852   Russian Federation
Bevacizumab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Breath test using THE compact PTR-TOF-MS
   I.M. Sechenov First Moscow State Medical University
      2023   -   NCT05727852   Russian Federation
Buccal (cheek) swab
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Celecoxib
   Brigham and Women's Hospital
      2016   Phase 2   NCT02484664   United States
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Doxycycline
   University of Nottingham
      2009   Phase 4   NCT00989742   United Kingdom
Doxycycline 100 MG capsules
   University of Nottingham
      2008   -   EUCTR2007-003745-32-GB   United Kingdom
Everolimus
   Children's Hospital Medical Center, Cincinnati
      2008   Phase 1/Phase 2   NCT00792766   United States
   NOVARTIS FARMA
      2010   -   EUCTR2010-019825-32-IT   France;Italy
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy
   Novartis Pharma Services AG
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01059318   France;Germany;Italy;United States
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   University of Cincinnati
      2015   -   NCT02432560   United States
Everolimus oral product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Glutamine
   Vanderbilt University Medical Center
      2019   Phase 1   NCT04388371   United States
Imatimib mesylate
   Columbia University
      2025   Phase 1   NCT06889168   United States
Imatinib mesylate 400MG capsule
   Medical University of South Carolina
      2018   Phase 1/Phase 2   NCT03131999   United States
Laboratory biomarker analysis
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Letrozole
   University of Cincinnati
      2011   Phase 2   NCT01353209   United States
Loratadina stada 10 MG
   IDIBELL (Institut d’Investigació Biomédica de Bellvitge)
      2021   Phase 2   EUCTR2020-000702-29-ES   Spain
Loratadine
   IDIBELL (Institut d’Investigació Biomédica de Bellvitge)
      2021   Phase 2   EUCTR2020-000702-29-ES   Spain
Nintedanib
   IRCCS Multimedica
      2016   Phase 2   NCT03062943   Italy
Octreotide
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00005906   United States
Ofev
   MULTIMEDICA S.P.A.
      2016   Phase 3   EUCTR2015-004919-20-IT   Italy
PFT
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States
Pharmacological study
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Phlebotomy
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Portable cardiac monitor cardioqvark
   I.M. Sechenov First Moscow State Medical University
      2023   -   NCT05727852   Russian Federation
RAD001
   Children's Hospital Medical Center, Cincinnati
      2008   Phase 1/Phase 2   NCT00792766   United States
      2005   Phase 1/Phase 2   NCT00457964   United States
   NOVARTIS FARMA
      2010   -   EUCTR2010-019825-32-IT   France;Italy
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy
   Novartis Pharma Services AG
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
RAD001 5MG
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
Rapamycin, sirolimus
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2   NCT00457808   United States
Resveratrol
   University of Cincinnati
      2018   Phase 2   NCT03253913   United States
Saracatinib
   Baylor College of Medicine
      2016   Phase 2   NCT02737202   United States
   Tony Eissa
      2014   Phase 1   NCT02116712   United States
Simvastatin
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Sirolimus
   Cardiff University
      2005   Phase 2   NCT00490789   United Kingdom
   Kobe University Graduate School of Medicine
      2012   -   JPRN-UMIN000007387   Japan
   Koh Nakata, MD, Ph.D
      2011   Phase 2   JPRN-jRCT1091220037   Japan
   Koh Nakata, MD, PhD
      2012   Phase 2   JPRN-jRCT2091220096   Japan
   Office of Rare Diseases (ORD)
      2006   Phase 3   NCT00414648   Canada;Japan;United States
   University of Cincinnati
      2018   Phase 2   NCT03253913   United States
      2018   Phase 3   NCT03150914   United States
      2015   -   NCT02432560   United States
Sirolimus 2MG
   Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicine
      2008   Phase 3   JPRN-jRCT2091220011   Canada;Japan;United States
   National Heart, Lung, and Blood Institute (NHLBI)
      2017   Phase 2   NCT03304678   United States
   National Hospital Organization Kinki-chuo Chest Medical Center
      2015   -   JPRN-UMIN000016677   Japan
Sirolimus and hydroxychloroquine 200 MG
   Brigham and Women's Hospital
      2012   Phase 1   NCT01687179   United States
Sirolimus and hydroxychloroquine 400 MG
   Brigham and Women's Hospital
      2012   Phase 1   NCT01687179   United States
Sirolimus oral product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Tissue donation after routine clinical procedure
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Valproic acid
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States